skip navigation

Skip Nav

AIDSinfo Drug Database

AIDSinfo Drug Database

Drugs by class

FDA-approved

Investigational

Boceprevir  Audio icon

Other Names: BOC, Victrelis
Drug Class: Opportunistic Infections and Coinfections
Chemical Image:
Click image to enlarge
boceprevir
boceprevir
Molecular Weight: 519.6825

What is boceprevir?

Boceprevir is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. The drug is approved for use in adults whose liver is damaged but still functioning and who have not been treated yet or who did not respond to previous treatment with the medicines interferon and ribavirin. Boceprevir is always used in combination with the two medicines peginterferon alfa and ribavirin.

HCV infection is an opportunistic infection. An opportunistic infection is an infection that occurs more frequently or is more severe in people with weakened immune systems—such as those infected with HIV—than in people with healthy immune systems.

The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association of the Infectious Diseases Society of America (IDSA-HIVMA), includes recommendations on the HIV-related use of boceprevir to treat chronic HCV infection (genotype 1).

What should I tell my health care provider before taking boceprevir?

Before taking boceprevir, tell your health care provider:

  • If you are allergic to boceprevir or any other medicines.
  • About any medical conditions you have or have had, for example, diabetes or liver problems.
  • About anything that could affect your ability to take medicines, such as difficulty swallowing or remembering to take pills.
  • If you are pregnant or plan to become pregnant. Do not take the required combination of boceprevir with peginterferon alfa and ribavirin if you are pregnant or your sexual partner is pregnant or plans to become pregnant. This is because the combination includes ribavirin, which may cause birth defects or death of an unborn baby. You or your sexual partner should not become pregnant while taking these medicines and for 6 months after treatment is over.
  • If you are breastfeeding or plan to breastfeed. Do not breastfeed if you are infected with HIV.
  • About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Ask your health care provider if there are interactions between boceprevir (and peginterferon alfa and ribavirin) and the other medicines you take.

How should I take boceprevir?

Take boceprevir according to your health care provider’s instructions. Your health care provider will tell you how much boceprevir to take and when to take it. Before you start boceprevir and each time you get a refill, read any printed information that comes with your medicine.

How should boceprevir be stored?

  • Store boceprevir capsules in the refrigerator, between 36°F to 46°F (2°C to 8°C). Boceprevir capsules may also be stored at room temperature, up to 77°F (25°C), for 3 months.
  • Keep boceprevir in a tightly closed container and away from heat.
  • Safely throw away boceprevir that is no longer needed or expired (out of date).
  • Keep boceprevir and all medicines out of reach of children.

Where can I find more information about boceprevir?

More information about boceprevir is available:

The above Patient Version drug summary is based on the following FDA label(s): Capsule.

Last Reviewed: May 7, 2013

Last Updated: May 7, 2013


Back to Top